GDP方案治疗复发或难治性弥漫大B细胞淋巴瘤临床分析

目的评价由吉西他滨(GEM)、顺铂(DDP)、地塞米松(DXM)组成的GDP方案治疗复发或难治性弥漫大B细胞淋巴瘤(DLBCL)的近期疗效和毒副作用。方法 2007年7月至2011年9月收治的17例复发或难治性DL-BCL患者,应用GDP方案化学治疗(GEM 1 000 mg.m-2,静脉滴注,第1、8天;DDP 25 mg.m-2,静脉滴注,第1～3天;DXM 10～40 mg.d-1,静脉滴注,第1～4天),每21 d重复1次,2个疗程后随访疾病进展情况,评价其疗效及毒副作用。结果 17例患者中5例(29.4%)获完全缓解,6例(35.3%)获部分缓解,主要不良反应为轻至中度的消化道反应和骨髓抑制。结论 GEM联合DDP、DXM的GDP方案治疗复发或难治性DLBCL的近期疗效较好,易耐受,安全性较高。

Clinical analysis of gemcitabine and cisplatin plus dexamethasone for treating relapsed or refractory diffuse large B-cell lymphoma

Objective To evaluate the short-term effects and side effects of adjuvant chemotherapy with gemcitabine,cisplatin and dexamethasone for patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL).Methods Seventeen patients with relapsed or refractory DLBCL were enrolled from July 2007 to September 2011,who received GDP regimen(gemcitabine 1 000 mg·m-2 intravenously on the first day and the eighth day,cisplatin 25 mg·m-2 intravenously from the first day to the third day,and dexamethasone 10-40 mg·d-1 intravenously from the first day to the fourth day).The treatment was repeated every 21 days.Efficacy and side effects were estimated after two cycles therapy by following up of the progression of DLBCL.Results Among 17 patients,5 cases achieved complete response and 6 cases achieved partial response.The major side effects were moderate gastrointestinal reaction and marrow suppression.Conclusion GDP has good short-term effects and is well tolerated for relapsed or refractory DLBCL with an acceptabe toxicity.